Lynparza

(Olaparib)

ApprovedSmall molecule

Olaparib is used to treat certain types of cancer, particularly ovarian and breast cancers that have a specific genetic mutation (BRCA mutation). It works by stopping cancer cells from repairing their DNA, causing them to die.[2] Lynparza is currently approved and in use across 94 indications[4].[1]

Lynparza is one of 1418 small molecule programs targeting Glioma. It is currently in Approved.

Indications

370

Total Trials

Active Trials

1,417

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

GliomaActive, not recruiting

Pancreatic CarcinomaApproved

Pancreatic NeoplasmActive, not recruiting

Bone MetastasisActive, not recruiting

Uterine LeiomyosarcomaActive, not recruiting

MetastasisApproved

Prostate AdenocarcinomaActive, not recruiting

ProstatitisApproved

Unspecified Peripheral T-Cell LymphomaApproved

Prostate CarcinomaApproved

GliomaPhase 2

Active, not recruiting

Pancreatic CarcinomaApproved

Approved

Pancreatic NeoplasmApproved

Active, not recruiting

Bone MetastasisPhase 1

Active, not recruiting

Uterine LeiomyosarcomaPhase 2

Active, not recruiting

MetastasisApproved

Approved

Prostate AdenocarcinomaPhase 2

Active, not recruiting

ProstatitisApproved

Approved

Unspecified Peripheral T-Cell LymphomaApproved

Approved

Prostate CarcinomaApproved

Approved

Showing 10 of 94 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Lynparza

AstraZeneca

Approved

45 2

Tykerb

GSK

Preclinical

80 3

Adriamycin

GGynecologic Oncology Group

Preclinical

87 4

Prolia

Amgen

Preclinical

14 5

Gemzar

GGynecologic Oncology Group

Preclinical

22 6

DATROWAY

Daiichi Sankyo

Preclinical

4 7

Lexiscan

Astellas

Preclinical

1 8

Adenocard

Astellas

Preclinical

1 9

Zolymbus

AbbVie

Preclinical

1 10

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Gynaecological Cancers

NCT04065269

Phase 1Active, not recruiting

Solid Tumors

NCT03162627

Phase 2Active, not recruiting

Phase II

NCT03334617

Phase 1/2Active, not recruiting

Patients With Advanced Solid Tumors

NCT02734004

Phase 1Active, not recruiting

Patients With Advanced Solid Tumors

NCT03842228

Phase 2Active, not recruiting

Lung Cancer

NCT03775486

Clinical

Trials by Indication[1]

Ovarian Cancer34 trials

Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT03402841·279 enrolled

A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.

Withdrawn· AstraZeneca logo

AstraZeneca·Phase 2·NCT04239014

Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations

Withdrawn· AstraZeneca logo

AstraZeneca·Phase 3·NCT02392676

Show 31 more trials

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

Recruiting·NNRG Oncology·Phase 3·NCT06580314·880 enrolled

Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer

Active, not recruiting·NNordic Society of Gynaecological Oncology - Clinical Trials Unit·Phase 2·NCT04742075·188 enrolled

Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer

Completed·UUniversity of Pennsylvania·Phase 2·NCT03462342·123 enrolled

Olaparib Maintenance With Pembrolizumab & Bevacizumab in BRCA Non-mutated Patients With Platinum-sensitive Recurrent Ovarian Cancer

Enrolling by invitation·YYonsei University·Phase 2·NCT04361370·44 enrolled

An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)

Unknown status·YYonsei University·Phase 2·NCT03699449·104 enrolled

Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients

Unknown status·UUniversity College, London·Phase 3·NCT03278717·330 enrolled

Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer

Unknown status·SSwedish Medical Center·Phase 1/2·NCT01650376·52 enrolled

Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT02282020·266 enrolled

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Terminated· Novartis logo

Novartis·Phase 3·NCT04729387·358 enrolled

To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT02476968·181 enrolled

A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer

Completed·UUniversity Health Network, Toronto·N/A·NCT02681237·34 enrolled

Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer

Unknown status·XXiaoxiang Chen·Phase 2·NCT04566952·68 enrolled

PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer

Active, not recruiting·NNew Mexico Cancer Research Alliance·Phase 1/2·NCT02571725·50 enrolled

Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer

Not yet recruiting·JJiangsu Cancer Institute & Hospital·Phase 2·NCT07407452·50 enrolled

Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian Cancer

Completed·NNational Cancer Center Hospital East·Phase 2·NCT04417192·30 enrolled

Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT05295589

Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer

Recruiting·UUniversity of Colorado, Denver·Phase 1·NCT06856499·50 enrolled

Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer

Recruiting·AAkeso·Phase 2·NCT06686030·150 enrolled

Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer

Completed·TThe Christie NHS Foundation Trust·Phase 1·NCT02855697·28 enrolled

Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT01081951·162 enrolled

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT01874353·327 enrolled

Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer

Terminated·SSarah E Taylor·Phase 2·NCT04377087·3 enrolled

A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer

Recruiting· Boryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd·Phase 1·NCT07069335·24 enrolled

Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT03534453·229 enrolled

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT01844986·450 enrolled

The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer

Recruiting·TThe Netherlands Cancer Institute·Phase 1/2·NCT07460180·55 enrolled

Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer

Withdrawn·—·Phase 2·NCT01661868

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT02345265·70 enrolled

Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer

Unknown status·—·Phase 2·NCT05158062·35 enrolled

Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Completed·UUniversity of Oxford·Phase 2·NCT03117933·139 enrolled

MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.

Recruiting·NNational Cancer Institute, Naples·Phase 3·NCT05255471·200 enrolled

Breast Cancer28 trials

Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.

Active, not recruiting·UUNICANCER·Phase 2·NCT04053322·172 enrolled

To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT03286842·256 enrolled

SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

Active, not recruiting·UUNICANCER·Phase 2·NCT02299999·1,460 enrolled

Show 25 more trials

Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT04191135·462 enrolled

Olaparib+Trastuzumab in HER2[+],Breast Cancer Susceptibility Gene (BRCA) Mutated Advanced Breast Cancer

Terminated·MMedSIR·Phase 2·NCT03931551·5 enrolled

The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial

Unknown status·IInstitute of Cancer Research, United Kingdom·Phase 2·NCT03182634·1,150 enrolled

Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT05967286

Olaparib + Sapacitabine in BRCA Mutant Breast Cancer

Active, not recruiting·—·Phase 1·NCT03641755·10 enrolled

Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer.

Completed·SSOLTI Breast Cancer Research Group·Phase 2·NCT05340413·65 enrolled

A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer

Terminated· AstraZeneca logo

AstraZeneca·Phase 1·NCT02561832·15 enrolled

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT04090567·60 enrolled

Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer

Completed·OOHSU Knight Cancer Institute·Phase 1·NCT03544125·3 enrolled

Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients

Unknown status·IIstituti Ospitalieri di Cremona·Phase 2·NCT02681562·45 enrolled

Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer

Completed·SSpanish Breast Cancer Research Group·Phase 2·NCT03205761·11 enrolled

Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00494234·54 enrolled

Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences

Terminated·TThomas Jefferson University·Phase 1·NCT03955640·3 enrolled

Olaparib and Radiotherapy in Inoperable Breast Cancer

Completed·TThe Netherlands Cancer Institute·Phase 1·NCT02227082·7 enrolled

Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer

Recruiting·—·Phase 2/3·NCT03150576·780 enrolled

Estradiol Plus Olaparib for Breast Cancer (PHOEBE)

Recruiting·MMary D Chamberlin·Phase 1·NCT05900895·6 enrolled

Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

Recruiting·OOkayama University·Phase 2·NCT05485766·23 enrolled

Olaparib Maintenance Therapy in Metastatic Breast Cancer

Unknown status·NNational Taiwan University Hospital·Phase 2·NCT05629429·300 enrolled

PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer

Recruiting·IInstitute of Cancer Research, United Kingdom·Phase 2·NCT03740893·119 enrolled

Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer

Completed·YYuan Yuan·Phase 2·NCT03025035·14 enrolled

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT02032823·1,836 enrolled

Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer

Recruiting·GGBG Forschungs GmbH·Phase 2·NCT06201234·176 enrolled

Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT02000622·302 enrolled

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

Recruiting·—·Phase 1·NCT06488378·20 enrolled

Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT04330040·202 enrolled

Prostate Cancer14 trials

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT05171816·110 enrolled

Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT02893917·90 enrolled

BrUOG 337: Olaparib Prior to Radical Prostatectomy For Advanced Prostate Cancer Defects in DNA Repair Genes

Terminated·—·Phase 2·NCT03432897·1 enrolled

Show 11 more trials

Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT05501548·4 enrolled

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT05457257·43 enrolled

Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

Withdrawn·NNational Cancer Institute (NCI)·Phase 1·NCT05807126

A Study of Olaparib and Durvalumab in Prostate Cancer

Terminated·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03810105·5 enrolled

Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer

Completed·UUniversity of Washington·Phase 2·NCT03516812·36 enrolled

Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)

Active, not recruiting·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT03787680·49 enrolled

Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load

Terminated·UUniversity of Washington·Phase 2·NCT04336943·6 enrolled

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT03732820·895 enrolled

177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer

Active, not recruiting·PPeter MacCallum Cancer Centre, Australia·Phase 1·NCT03874884·70 enrolled

Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT02987543·387 enrolled

Carboplatin or Olaparib for BRcA Deficient Prostate Cancer

Recruiting·VVA Office of Research and Development·Phase 2·NCT04038502·100 enrolled

Advanced Solid Tumours5 trials

Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal or Impaired Kidney Function

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT01894256·56 enrolled

Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT01894243·31 enrolled

Study to Assess the Effect of Rifampicin (CYP Inducer) on Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT01929603·32 enrolled

Show 2 more trials

To Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of Olaparib, and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation to Patients With Advanced Solid Tumours

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT01900028·85 enrolled

A Study Using Olaparib Tablets for Subjects With Advanced Solid Tumours.

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT03553108·18 enrolled

Advanced Solid Tumors4 trials

Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors

Active, not recruiting·UUniversity Health Network, Toronto·Phase 2·NCT03851614·90 enrolled

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT02498613·122 enrolled

Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors

Terminated·RRepare Therapeutics·Phase 1·NCT06560632·26 enrolled

Show 1 more trial

Study of INCB123667 in Subjects With Advanced Solid Tumors

Recruiting· Incyte logo

Incyte·Phase 1·NCT05238922·604 enrolled

79 more indications

Pancreatic Cancer4 trials

Efficacy and Safety of PARPi to Treat Pancreatic Cancer

Completed·SSheba Medical Center·Phase 2·NCT02511223·24 enrolled

Olaparib and Durvalumab (MEDI4736) in Patients with Metastatic Pancreatic Cancer and DNA Damage Repair Genes Alterations

Active, not recruiting·SSpanish Cooperative Group for the Treatment of Digestive Tumours (TTD)·Phase 2·NCT05659914·40 enrolled

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

Recruiting·OOHSU Knight Cancer Institute·Phase 1·NCT04005690·90 enrolled

Show 1 more trial

Olaparib in Treating Patients With Stage IV Pancreatic Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02677038·24 enrolled

Small Cell Lung Cancer4 trials

Olaparib and Bevacizumab in Relapsed Small Cell Lung Cancer Subjects

Completed·SSe-Hoon Lee·Phase 2·NCT04939662·25 enrolled

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT03923270·25 enrolled

A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT03532880·26 enrolled

Show 1 more trial

EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer

Withdrawn·EEllipses Pharma·Phase 2·NCT05411679

Non-Small Cell Lung Cancer4 trials

Trial Evaluating Maintenance Olaparib in Patients With Platinum-sensitive Advanced Non-small Cell Lung Cancer

Unknown status·GGustave Roussy, Cancer Campus, Grand Paris·Phase 2·NCT02679963·600 enrolled

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT04380636·870 enrolled

A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT03976362·851 enrolled

Show 1 more trial

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT06130254·52 enrolled

Endometrial Cancer4 trials

A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT05156268·26 enrolled

Effects of PARP Inhibitor on Tumor Microenvironment in High-risk Endometrial Cancer Patients

Completed·TThe University of Hong Kong·Phase 1·NCT05320757·20 enrolled

Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel?

Unknown status·UUniversity of Manchester·Phase 2·NCT03570437·124 enrolled

Show 1 more trial

Refining Adjuvant Treatment in Endometrial Cancer Based on Molecular Features

Recruiting·LLeiden University Medical Center·Phase 2/3·NCT05255653·1,615 enrolled

Fallopian Tube Cancer3 trials

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT03579316·96 enrolled

Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT02121990·17 enrolled

Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers

Terminated·VVanderbilt-Ingram Cancer Center·Phase 1·NCT03924245·3 enrolled

Gastric Cancer3 trials

Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT01924533·525 enrolled

A Translational Study of Single Agent Olaparib in the Treatment of Advanced Oesophagogastric Cancer

Unknown status·RRoyal Marsden NHS Foundation Trust·Phase 2·NCT03829345·54 enrolled

Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer

Active, not recruiting·DDo-Youn Oh·Phase 2·NCT03579784·40 enrolled

Biliary Tract Cancer3 trials

Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy

Recruiting·—·Phase 2·NCT05222971·62 enrolled

DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer

Active, not recruiting·SSeoul National University Hospital·Phase 2·NCT04298021·74 enrolled

Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

Unknown status·—·Phase 2·NCT04042831·36 enrolled

Patients With Advanced Solid Tumors3 trials

Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT03842228·39 enrolled

A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 1/2·NCT02734004·264 enrolled

NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Terminated·NNuvation Bio Inc.·Phase 1·NCT05252390·82 enrolled

Efficacy and Safety3 trials

A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors

Active, not recruiting· Roche logo

Roche·Phase 2·NCT04931342·176 enrolled

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT01078662·298 enrolled

Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor

Recruiting·SSeoul National University Hospital·Phase 2·NCT05536128·64 enrolled

Lymphoma2 trials

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT03205176·49 enrolled

Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT03259503·50 enrolled

Lung Cancer2 trials

Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)

Enrolling by invitation·UUniversity of Cologne·Phase 2·NCT06419179·29 enrolled

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT03775486·401 enrolled

Trial2 trials

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

Recruiting·CCanadian Cancer Trials Group·Phase 2·NCT03297606·720 enrolled

The Drug Rediscovery Protocol (DRUP Trial)

Recruiting·TThe Netherlands Cancer Institute·Phase 2·NCT02925234·1,550 enrolled

Pembrolizumab2 trials

Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer

Recruiting·YYonsei University·Phase 1/2·NCT04592211·71 enrolled

Pembrolizumab Plus Olaparib in LA-HNSCC

Active, not recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT05366166·45 enrolled

PARP Inhibitor2 trials

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined with the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

Recruiting·FFundación de investigación HM·Phase 2·NCT06607692·25 enrolled

Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors

Terminated·TTango Therapeutics, Inc.·Phase 1/2·NCT06065059·7 enrolled

Maintenance Therapy2 trials

First-line Olaparib Combined With Bevacizumab Maintenance Therapy

Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University··NCT05440578·50 enrolled

Outcomes of First-line Olaparib Mono-maintenance therapy-a Multicenter, Retrospective Study Using Data From Real-world Clinical Setting

Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University··NCT05153603·50 enrolled

Bladder Cancer2 trials

Durvalumab Plus Olaparib Administered Prior to Surgery of Resectable Urothelial Bladder Cancer (NEODURVARIB)

Completed·SSpanish Oncology Genito-Urinary Group·Phase 2·NCT03534492·29 enrolled

Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT02546661·117 enrolled

Solid Tumors2 trials

Selumetinib and Olaparib in Solid Tumors

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT03162627·90 enrolled

Study of Olaparib/Trabectedin vs. Doctor's Choice in Solid Tumors

Completed·NNational Center for Tumor Diseases, Heidelberg·Phase 2·NCT03127215·102 enrolled

Cervical Cancer2 trials

Pembrolizumab and Olaparib in Cervical Cancer Patients

Terminated·BBaptist Health South Florida·Phase 2·NCT04483544·8 enrolled

Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer

Unknown status·—·Phase 2·NCT04641728·28 enrolled

Phase II2 trials

A Two-stage Simon Design Phase II Study for Non-BRCA MBC Patients With HRD Treated With Olaparib Single Agent

Terminated·MMedSIR·Phase 2·NCT03367689·7 enrolled

Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT03334617·528 enrolled

Triple-Negative Breast Cancer2 trials

Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer

Not yet recruiting·HHebei Medical University Fourth Hospital·Phase 2·NCT05522491·30 enrolled

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1/2·NCT01116648·155 enrolled

Ewing's Sarcoma2 trials

Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma

Completed·MMassachusetts General Hospital·Phase 2·NCT01583543·12 enrolled

Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma

Completed·MMassachusetts General Hospital·Phase 1·NCT01858168·49 enrolled

Uterine Leiomyosarcoma2 trials

A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03880019·23 enrolled

Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2/3·NCT05432791·73 enrolled

Advanced Solid Malignancies1 trial

Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT01813474·23 enrolled

Tic Disorder1 trial

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03155620·1,376 enrolled

Bevacizumab1 trial

Status of HRD That Lead to a Benefit From Olaparib in Combination With Bevacizumab (STROBE Trial)

Recruiting·VVall d'Hebron Institute of Oncology·Phase 2·NCT06377267·100 enrolled

Pancreatic Acinar Cell Carcinoma1 trial

Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT05286827·5 enrolled

Advanced or Metastatic Solid Tumors1 trial

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

Recruiting·MMOMA Therapeutics·Phase 1·NCT06545942·220 enrolled

Recurrent1 trial

Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib

Completed· Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research·Phase 2·NCT03314740·123 enrolled

Glioma1 trial

Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients

Active, not recruiting·CCentre Francois Baclesse·Phase 1/2·NCT03212742·91 enrolled

Outcome1 trial

Olaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UK

Completed· AstraZeneca logo

AstraZeneca··NCT04532645·342 enrolled

Immunotherapy1 trial

Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment

Active, not recruiting·CCentre Georges Francois Leclerc·Phase 2·NCT04169841·270 enrolled

Hypertension1 trial

Arterial Hypertension Related to PARP Inhibitors (ArteRIB)

Completed·UUniversity Hospital, Caen··NCT04774406·2,336 enrolled

Fed1 trial

Bioequivalence Study of Olaparib Tablets Under Fasting and Fed Conditions in Healthy Subjects

Completed·CCSPC Ouyi Pharmaceutical Co., Ltd.·Phase 1·NCT06360445·102 enrolled

RCT1 trial

D9319C00001- 1L OC Mono Global RCT

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT04884360·366 enrolled

Metastatic Sarcoma1 trial

Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT04076579·29 enrolled

Head and Neck Squamous Cell Carcinoma1 trial

A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT03022409·21 enrolled

Solid Tumour1 trial

The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour.

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02430311·36 enrolled

Advanced Stage Cancer1 trial

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Recruiting·AAmerican Society of Clinical Oncology·Phase 2·NCT02693535·4,200 enrolled

HRR Gene Mutation1 trial

The Study of Olaparib in Newly Diagnosed mCRPC Patients With HRR Gene Mutation

Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT05262608·30 enrolled

Newly Diagnosed1 trial

Study of Pamiparib in Newly Diagnosed and rGBM

Active, not recruiting·NNader Sanai·Phase 1·NCT04614909·45 enrolled

Terminated·LLatin American Cooperative Oncology Group·Phase 2·NCT04579133·140 enrolled

Effectiveness1 trial

Pharmacokinetic Boosting of Olaparib to Improve Exposure, Tolerance and Cost-effectiveness

Recruiting·RRadboud University Medical Center·Phase 4·NCT05078671·160 enrolled

Chemotherapy1 trial

Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.

Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT04753879·38 enrolled

Renal Cell Carcinoma1 trial

Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations

Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT03786796·20 enrolled

Endometrial Carcinoma1 trial

Preoperative Olaparib Endometrial Carcinoma Study (POLEN)

Completed·MMedSIR··NCT02506816·36 enrolled

Primary Peritoneal Cancer1 trial

Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

Completed·RRoswell Park Cancer Institute·Phase 2·NCT02953457·40 enrolled

Neuroendocrine Cancer1 trial

Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04394858·46 enrolled

Clinical Trial1 trial

Olaparib for PAH: a Multicenter Clinical Trial

Terminated·LLaval University·Phase 1/2·NCT03782818·17 enrolled

Renal Cell Cancer1 trial

WIRE - Novel Treatments in Renal Cell Cancer

Unknown status·CCCTU- Cancer Theme·Phase 2·NCT03741426·60 enrolled

Surgical1 trial

Surgical Pembro +/- Olaparib w TMZ for rGBM

Recruiting·—·Phase 2·NCT05463848·78 enrolled

Advanced Sarcoma1 trial

Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS)

Completed·IItalian Sarcoma Group·Phase 1·NCT02398058·50 enrolled

Randomized1 trial

IMPACT: A Randomized WOO Study of Novel Therapeutic Agents in Women Triaged to Primary Surgery for EOC

Completed·HHaukeland University Hospital·Phase 1·NCT03378297·26 enrolled

Safety and Efficacy1 trial

Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors

Completed·VValerio Therapeutics·Phase 1/2·NCT05700669·3 enrolled

Gastric Adenocarcinoma1 trial

Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma

Active, not recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT04209686·36 enrolled

Pancreatic Ductal Adenocarcinoma1 trial

A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04666740·63 enrolled

Glioblastoma1 trial

Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma

Completed·CCancer Research UK·Phase 1·NCT01390571·34 enrolled

Advanced1 trial

Study to Evaluate CCS1477 in Advanced Tumours

Completed·CCellCentric Ltd.·Phase 1/2·NCT03568656·220 enrolled

Metastatic Melanoma1 trial

Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2

Withdrawn·—·Phase 2·NCT05482074

Peritoneal Cancer1 trial

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04034927·61 enrolled

Metastatic Colorectal Cancer1 trial

AZD2281 and Irinotecan in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer

Completed·NNCIC Clinical Trials Group·Phase 1·NCT00535353·26 enrolled

Colorectal Cancer1 trial

Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC).

Unknown status·GGrupo Espanol Multidisciplinario del Cancer Digestivo·Phase 2·NCT05201612·40 enrolled

Function1 trial

Functional Analysis of BRCAness

Terminated·LLeiden University Medical Center·Phase 2·NCT04780945·27 enrolled

Gynaecological Cancers1 trial

ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss

Active, not recruiting·IInstitute of Cancer Research, United Kingdom·Phase 2·NCT04065269·174 enrolled

Prostate Adenocarcinoma1 trial

Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma

Terminated·UUniversity of Washington·Phase 2·NCT04951492·2 enrolled

Cancer1 trial

OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults

Unknown status·UUniversity Medical Center Groningen·Phase 4·NCT05949424·30 enrolled

Advanced/Metastatic Solid Tumors1 trial

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients

Active, not recruiting·AArtios Pharma Ltd·Phase 1/2·NCT05898399·220 enrolled

Cholangiocarcinoma1 trial

Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

Recruiting·AAustralasian Gastro-Intestinal Trials Group·Phase 2·NCT06441747·40 enrolled

Patients With Solid Tumors1 trial

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Recruiting·RRahul Aggarwal·Phase 2·NCT03682289·89 enrolled

Tumors1 trial

Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03878095·24 enrolled

Malignant Mesothelioma1 trial

Olaparib in Patients With HRD Malignant Mesothelioma

Recruiting·UUniversity of Chicago·Phase 2·NCT04515836·56 enrolled

Phase 21 trial

AMTEC IIT: Phase 2 Multiarm Study in TNBC

Terminated·—·Phase 2·NCT03801369·24 enrolled

Pilot Study1 trial

Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

Terminated·PPeter MacCallum Cancer Centre, Australia·N/A·NCT04801966·3 enrolled

Ovarian Carcinoma1 trial

Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma

Completed·GGrupo Español de Investigación en Cáncer de Ovario·Phase 2·NCT03470805·9 enrolled

Treatment1 trial

Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL)

Completed·SSpanish Oncology Genito-Urinary Group·Phase 2·NCT03434158·16 enrolled

Gastroesophageal Junction Cancer1 trial

Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT03008278·51 enrolled

Unspecified2 trials

Pembro With Radiation With or Without Olaparib

Recruiting·ZZin W Myint·Phase 2·NCT05568550·64 enrolled

Platine, Avastin and OLAparib in 1st Line

Completed·AArcagy Research·Phase 3·NCT02477644·806 enrolled

Regulatory

FDA Approval Timeline[5]

Dec 19, 2014

LYNPARZA

NDA NDA206162

Aug 17, 2017

LYNPARZA

NDA NDA208558

Sources

References

[1]
ClinicalTrials.gov — 370 trial records for Olaparib. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Lynparza drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Olaparib compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Olaparib. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA208558). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Lynparza. U.S. Food & Drug Administration.
[7]
PubMed — 2 publications indexed for Olaparib. U.S. National Library of Medicine.
[8]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: PARP Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: AstraZeneca

Patent Landscape[6]

Patent Cliff

Sep 8, 2027

Earliest patent expiration — generic entry possible after this date

Patent #Expires

7449464Sep 8, 2027

8247416Sep 24, 2028

11975001Oct 7, 2029

11633396Oct 7, 2029

12144810Oct 7, 2029

4 more patents

12048695Oct 7, 2029

12178816Oct 7, 2029

8475842Dec 31, 2029

11970530Oct 25, 2041

Key Publications[7]

Adjuvant Olaparib for BRCA-Mutated Breast Cancer: OlympiA Overall Survival

N Engl J MedDec 8, 2022DOI: 10.1056/NEJMoa2208644

Olaparib Plus Abiraterone in Metastatic Castration-Resistant Prostate Cancer

Lancet OncolAug 1, 2022DOI: 10.1016/S1470-2045(22)00432-1

Lynparza

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Ovarian Cancer34 trials

Breast Cancer28 trials

Prostate Cancer14 trials

Advanced Solid Tumours5 trials

Advanced Solid Tumors4 trials

Pancreatic Cancer4 trials

Small Cell Lung Cancer4 trials

Non-Small Cell Lung Cancer4 trials

Endometrial Cancer4 trials

Fallopian Tube Cancer3 trials

Gastric Cancer3 trials

Biliary Tract Cancer3 trials

Patients With Advanced Solid Tumors3 trials

Efficacy and Safety3 trials

Lymphoma2 trials

Lung Cancer2 trials

Trial2 trials

Pembrolizumab2 trials

PARP Inhibitor2 trials

Maintenance Therapy2 trials

Bladder Cancer2 trials

Solid Tumors2 trials

Cervical Cancer2 trials

Phase II2 trials

Triple-Negative Breast Cancer2 trials

Ewing's Sarcoma2 trials

Uterine Leiomyosarcoma2 trials

Advanced Solid Malignancies1 trial

Tic Disorder1 trial

Bevacizumab1 trial

Pancreatic Acinar Cell Carcinoma1 trial

Advanced or Metastatic Solid Tumors1 trial

Recurrent1 trial

Glioma1 trial

Outcome1 trial

Immunotherapy1 trial

Hypertension1 trial

Fed1 trial

RCT1 trial

Metastatic Sarcoma1 trial

Head and Neck Squamous Cell Carcinoma1 trial

Solid Tumour1 trial

Advanced Stage Cancer1 trial

HRR Gene Mutation1 trial

Newly Diagnosed1 trial

Neoadjuvant Therapy1 trial

Primary Peritoneal Carcinoma1 trial

Adenocarcinoma1 trial

Urothelial Carcinoma1 trial

Effectiveness1 trial

Chemotherapy1 trial

Renal Cell Carcinoma1 trial

Endometrial Carcinoma1 trial

Primary Peritoneal Cancer1 trial

Neuroendocrine Cancer1 trial

Clinical Trial1 trial

Renal Cell Cancer1 trial

Surgical1 trial

Advanced Sarcoma1 trial

Randomized1 trial

Safety and Efficacy1 trial

Gastric Adenocarcinoma1 trial

Pancreatic Ductal Adenocarcinoma1 trial

Glioblastoma1 trial

Advanced1 trial

Metastatic Melanoma1 trial

Peritoneal Cancer1 trial

Metastatic Colorectal Cancer1 trial

Colorectal Cancer1 trial

Function1 trial

Gynaecological Cancers1 trial

Prostate Adenocarcinoma1 trial

Cancer1 trial

Advanced/Metastatic Solid Tumors1 trial